News | November 04, 2024
Briefs: Sun Pharmaceutical Industries and Biocon Biologics
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Subscribe To Our Newsletter & Stay Updated
